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Purpose or Objective: A majority of patients with rectal 
cancer is treated with neoadjuvant radiotherapy, with or 
without chemotherapy. If after chemoradiation (CRT) 
patients show a good clinical response, organ-preserving 
strategies are increasingly being offered. To increase the 
amount of patients with a good clinical response, it has been 
proposed to replace short-course radiotherapy (SCRT) by 
CRT. However, intensified treatment may affect patients’ 
quality of life (QoL). This study aims to compare self-
reported QoL between routinely treated rectal cancer 
patients receiving SCRT versus CRT before, during and after 
treatment. 
 
Material and Methods: This multicenter prospective cohort 
study includes rectal cancer patients of all stages referred 
for radiotherapy between February 2013 and May 2015. QoL 
was assessed by EORTC-C30 and -CR29 questionnaires at 
baseline, 3, 6 and 12 months. For each patient, a propensity 
score (PS) for receiving CRT was calculated and used for 
restriction and adjustment. Changes in QoL over time were 
analyzed by mixed models between patients receiving CRT 
and SCRT, and additionally compared to a normative age-
matched Dutch population. 
 
Results: After PS based restriction, 191 of 208 eligible 
patients were included, of which 69 underwent SCRT and 122 
CRT. Patients undergoing CRT were younger (62.2 vs. 68.0 
year), had more mesorectal fascia invasion (66.6% vs. 27.9%), 
more T4 (20.5% vs. 11.6%) and less T2 tumors (3.3% vs. 
11.6%). Questionnaire return rates were 84% at baseline and 
63-80% during follow-up. In both groups, 3 and 6 months QoL 
scores for global health, physical, emotional, social and role 
function were lower than at baseline and similar in both 
groups at all time points. At 12 months, all functional scores 
in both groups returned to baseline level, except for role 
function. No significant differences were found on symptom 
scales (constipation, diarrhea, pain, fatigue, nausea) 
between SCRT- and CRT-patients. Compared to the Dutch 
reference population, patients with rectal cancer still had 
impaired role and social function at 12 months. 
 
 
Conclusion: Over the course of neoadjuvant rectal cancer 
treatment, similar drops in QoL are observed for patients 
receiving SCRT or CRT. After 12 months, most QoL scores 
return to baseline levels. 
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Purpose or Objective: Protontherapy is a standard treatment 
for uveal melanomas. One area of current controversy is the 
use of protontherapy for uveal melanomas of temporal 
superior location owing to the presence of the lacrimal gland 
and the risk of radiation-induced dry eye syndrome (DES). 
Some teams have been contra-indicating such tumor locations 
for protontherapy and advocate brachytherapy. We 
investigated whether temporal superior (TS) melanomas 
should no longer be treated with proton therapy based on the 
rate of severe non manageable complications for DES. 
 
Material and Methods: This retrospective study includes 
consecutive patients treated from 1999 to 2014 with 
protontherapy at our center. Patients received 52 Gy in four 
fractions and four days. Conjunctival melanomas were not 
excluded. Melanoma location was determined using an 
oriented clockwise goniometer. DES grades were defined as 
Group 0 : no sign of dry eye, group 1: discomfort, group 2: 
keratitis, group 3 (severe): corneal ulcer. Percentages of the 
lacrimal gland receiving 90% of the prescribed dose, 20% to 
50% or ≤ 20% were assessed in the frontal and sagittal planes 
in Eyeplan blindly by two operators. The spss v12 statistics 
software was used. Kaplan Meier curves and Log rank tests 
were used for survival data. 
 
Results: Of 1445 patients in the study, 14.7% and 2.0% had 
DES and severe DES, respectively. Two and five year DES-free 
survival rates were 88.9% and 83.6%, respectively. There 
were 7.6% melanomas of TS location. DES and severe DES 
